BRIEF-Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results In Phase 2A Trial Of Lp-310 For Oral Lichen Planus

Reuters2024-09-24

Sept 24 (Reuters) - Lipella Pharmaceuticals Inc

* LIPELLA PHARMACEUTICALS REPORTS ENCOURAGING EARLY TOLERABILITY RESULTS IN PHASE 2A TRIAL OF LP-310 FOR ORAL LICHEN PLANUS

* LIPELLA PHARMACEUTICALS INC - LP-310 TREATMENT WELL TOLERATED WITH NO UNPLEASANT TASTE

* LIPELLA PHARMACEUTICALS INC - TRIAL TO CONCLUDE BY MID-2025, TOP-LINE DATA BY YEAR-END 2024

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2469366460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-24 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2469366460","market":"us","top_or_hot":-1,"title":"BRIEF-Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results In Phase 2A Trial Of Lp-310 For Oral Lichen Planus","media":"Reuters","content":"<html><body><p>Sept 24 (Reuters) - <a href=\"https://laohu8.com/S/LIPO\">Lipella Pharmaceuticals Inc</a></p><p> :</p><p>   * LIPELLA PHARMACEUTICALS REPORTS ENCOURAGING EARLY TOLERABILITY RESULTS IN PHASE 2A TRIAL OF LP-310 FOR ORAL LICHEN PLANUS</p><p>   * LIPELLA PHARMACEUTICALS INC - LP-310 TREATMENT WELL TOLERATED WITH NO UNPLEASANT TASTE</p><p>   * LIPELLA PHARMACEUTICALS INC - TRIAL TO CONCLUDE BY MID-2025, TOP-LINE DATA BY YEAR-END 2024</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results In Phase 2A Trial Of Lp-310 For Oral Lichen Planus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results In Phase 2A Trial Of Lp-310 For Oral Lichen Planus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-24 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 24 (Reuters) - Lipella Pharmaceuticals Inc :   * LIPELLA PHARMACEUTICALS REPORTS ENCOURAGING EARLY TOLERABILITY RESULTS IN PHASE 2A TRIAL OF LP-310 FOR ORAL LICHEN PLANUS   * LIPELLA ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LIPO","symbol_name":"Lipella Pharmaceuticals Inc","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2469366460","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2469366460","pubTimestamp":1727179553,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 24  - Lipella Pharmaceuticals Inc :   * LIPELLA PHARMACEUTICALS REPORTS ENCOURAGING EARLY TOLERABILITY RESULTS IN PHASE 2A TRIAL OF LP-310 FOR ORAL LICHEN PLANUS   * LIPELLA PHARMACEUTICALS INC - LP-310 TREATMENT WELL TOLERATED WITH NO UNPLEASANT TASTE   * LIPELLA PHARMACEUTICALS INC - TRIAL TO CONCLUDE BY MID-2025, TOP-LINE DATA BY YEAR-END 2024Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LIPO":"Lipella Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"简介-Lipella Pharmaceuticals报告了Lp-310治疗口腔扁平苔藓的2A期试验中令人鼓舞的早期耐受性结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIPO":0.9},"content_text":"Sept 24 (Reuters) - Lipella Pharmaceuticals Inc :   * LIPELLA PHARMACEUTICALS REPORTS ENCOURAGING EARLY TOLERABILITY RESULTS IN PHASE 2A TRIAL OF LP-310 FOR ORAL LICHEN PLANUS   * LIPELLA PHARMACEUTICALS INC - LP-310 TREATMENT WELL TOLERATED WITH NO UNPLEASANT TASTE   * LIPELLA PHARMACEUTICALS INC - TRIAL TO CONCLUDE BY MID-2025, TOP-LINE DATA BY YEAR-END 2024Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2469366460"}